TABLE 1.

Pretreatment characteristics for 120 patients with diffuse CRC liver metastases undergoing IHP

Demographics
Number of patients treated with IHP	120
Age (years, range)	52 (22–74)
Female: male	41:79
Tumor characteristics
No. of metastatic lesions (median/range)	8 (1–50)
Percentage liver replaced by tumor (median/range)	20% (5–75%)
Preoperative CEA level a
Normal	14
High stable	15
High increasing	81
Unknown	10
Site of primary tumor
Left colon	17
Right colon	6
Colon	28
Rectal	25
Sigmoid	39
Transverse	5
Liver metastasis
Synchronous metastasis	79
Metachronous	41
Prior chemotherapy
None	26
Yes	94
Chemotherapy for established liver tumors (5FU/LV and irinotecan), HAI	74
Chemotherapy as preventative treatment to dev. liver mets (5FU/LV—at least 4 cycles)	20
No chemotherapy of any kind	26

5FU = 5-fluorouracil, LV = leucovorin

^aUpper limit of normal for CEA is 3.5 ng/mL